Corvus Pharmaceuticals, Inc.

NasdaqGM:CRVS 株式レポート

時価総額:US$591.1m

Corvus Pharmaceuticals 過去の業績

過去 基準チェック /06

Corvus Pharmaceuticals は平均年間 6.6% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。19.3% です。

主要情報

6.6%

収益成長率

21.6%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率n/a
株主資本利益率-44.1%
ネット・マージンn/a
次回の業績アップデート12 Nov 2024

最近の業績更新

Recent updates

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

収支内訳

Corvus Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:CRVS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 240-23716
31 Mar 240-25716
31 Dec 230-27717
30 Sep 230-30717
30 Jun 230-39723
31 Mar 230-41724
31 Dec 220-41824
30 Sep 220-41825
30 Jun 220-37822
31 Mar 220-40826
31 Dec 210-43929
30 Sep 210-71032
30 Jun 210-61131
31 Mar 210-51230
31 Dec 200-61232
30 Sep 200-441234
30 Jun 200-461136
31 Mar 200-481139
31 Dec 190-471138
30 Sep 190-461137
30 Jun 190-461137
31 Mar 190-441136
31 Dec 180-471139
30 Sep 180-481040
30 Jun 180-511042
31 Mar 180-541045
31 Dec 170-561046
30 Sep 170-551046
30 Jun 170-521043
31 Mar 170-46937
31 Dec 160-36829
30 Sep 160-31724
30 Jun 160-24519
31 Mar 160-36414
31 Dec 150-31211
30 Sep 150-2516

質の高い収益: CRVSは現在利益が出ていません。

利益率の向上: CRVSは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CRVSは利益を出していないが、過去 5 年間で年間6.6%の割合で損失を削減してきた。

成長の加速: CRVSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CRVSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: CRVSは現在利益が出ていないため、自己資本利益率 ( -44.15% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘